Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
6.64%
Grew
—
—
Shrank
—
1 Year
Score—
Net Growth6.64%
Net TrendGrew
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
2.6
-12.59%
40%
—
-100.00%
Never
—
5 Years
Score2.6
Net Growth-12.59%
Net Trend40%
Net Income Consistency—
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency—
Acumen Pharmaceuticals Inc fundamental performance
Between 2021 and 2025, revenue declined from $ 1M to $ 0.00 and net income went from -$ 100M to -$ 121M. Revenue increased in 0% of the years measured; net income in 40%.
Acumen Pharmaceuticals Inc currently holds a 5-year HDB Score of 2.6 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 2.51 | — |
1 Year2025-08-12 | $ 1.26 | 99.21% |
5 Years2021-08-12 | $ 14.90 | -83.15% |
All Time2021-07-01 | $ 20.10 | -87.51% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2021-07-01 |
|---|---|---|---|---|
| Price | $ 2.51 | $ 1.26 | $ 14.90 | $ 20.10 |
| Return | — | 99.21% | -83.15% | -87.51% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 0.00 | -$ 113M | $ 128M |
| 2025 | $ 0.00 | -$ 121M | $ 116M |
| 2024 | $ 0.00 | -$ 102M | $ 171M |
| 2023 | $ 0.00 | -$ 52M | $ 243M |
| 2022 | $ 0.00 | -$ 42M | $ 177M |
| IPO2021 | $ 1M | -$ 100M | $ 194M |
Explore beyond ABOS
You're looking at Acumen Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
